SCHEMBL22200463

SCHEMBL22200463

CC(C)n1c(=O)c(-c2cc(F)c(N)c(F)c2)nc2cnc(N)nc21

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MTOR P42345 7/20 0.44
ERN1 O75460 2/20 0.40
CYP1A2 P05177 9/20 0.39
ALDH1A1 P00352 7/20 0.39
USP2 O75604 5/20 0.39
HSD17B10 Q99714 5/20 0.39
CASP1 P29466 4/20 0.39
CASP7 P55210 4/20 0.39
CYP3A4 P08684 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PIK3CA P42336 4/20 0.39
CLK4 Q9HAZ1 2/20 0.39
TSHR P16473 2/20 0.39
HIF1A Q16665 2/20 0.38
GLA P06280 2/20 0.38
CYP2C9 P11712 2/20 0.36
MAPK1 P28482 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200709 0.87 KDM5B (0.45) MTORERN1CYP1A2ALDH1A1USP2
SCHEMBL25034135 0.81 ERN1 (0.50) MTORERN1CYP1A2ALDH1A1USP2
SCHEMBL22200719 0.80 ERN1 (0.42) MTORERN1CYP1A2ALDH1A1USP2
SCHEMBL22200437 0.80 MTOR (0.52) MTORCYP1A2ALDH1A1USP2HSD17B10
SCHEMBL25034211 0.79 ERN1 (0.52) MTORERN1CYP1A2ALDH1A1USP2
SCHEMBL22200635 0.79 ERN1 (0.39) ERN1CYP1A2ALDH1A1USP2HSD17B10
SCHEMBL22200788 0.79 USP2 (0.40) ERN1CYP1A2ALDH1A1USP2HSD17B10
SCHEMBL25035485 0.78 ERN1 (0.48) MTORERN1CYP1A2ALDH1A1USP2
SCHEMBL25035643 0.78 ERN1 (0.51) MTORERN1CYP1A2ALDH1A1USP2
SCHEMBL25034190 0.78 ERN1 (0.48) ERN1CYP1A2ALDH1A1USP2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed